Skip to main content
SpringerLink
Log in

Bevacizumab

Various toxicities: 4 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Identifying patient details (age and sex) have been obtained through direct communication with the author.

Reference

  • Katic K, et al. First-line treatment of ovarian cancer FIGO stages IIIB-IV: Focus on therapy with bevacizumab - Our experience. Libri Oncologici 47: 64-70, No. 2, Jan 2019. Available from: URL: http://doi.org/10.20471/LO.2019.47.02-03.12

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bevacizumab. Reactions Weekly 1810, 49 (2020). https://doi.org/10.1007/s40278-020-80069-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-80069-2

Search

Navigation